Literature DB >> 6208668

Presence of an abnormal transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy.

M J Saraiva, P P Costa, S Birken, D S Goodman.   

Abstract

In summary, these studies have demonstrated the following: 1) plasma TTR levels are significantly decreased in Portuguese patients with FAP; 2) FAP-TTR is indistinguishable from normal TTR with regard to a wide range of physiochemical properties; 3) RBP levels and vitamin A transport appear to be normal in FAP patients; 4) an abnormal TTR with a methionine for valine substitution at position 30 is found as amyloid protein in tissues of patients with FAP; and 5) this abnormal TTR is present in small amounts in plasma of patients with FAP. Based on these observations, we postulate that this abnormal form of TTR selectively deposits in tissues as the amyloid characteristic of the disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6208668

Source DB:  PubMed          Journal:  Trans Assoc Am Physicians        ISSN: 0066-9458


  29 in total

1.  Plasma catecholamines and postural hypotension in familial amyloidotic polyneuropathy of the Portuguese type.

Authors:  J Ducla-Soares; L Breitenfeld; P Póvoa; M Ferreira; M Carvalho; M Alves; M Bicho; M de L Sales-Luis; C Manso; A da Palma-Carlos
Journal:  Clin Auton Res       Date:  1991-12       Impact factor: 4.435

2.  Prenatal diagnosis of familial amyloidotic polyneuropathy: evidence for an early expression of the associated transthyretin methionine 30.

Authors:  M R Almeida; I L Alves; Y Sakaki; P P Costa; M J Saraiva
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

3.  Diagnosis of the type of amyloid in paraffin wax embedded tissue sections using antisera against human and animal amyloid proteins.

Authors:  C A van de Kaa; P R Hol; J Huber; R P Linke; C J Kooiker; E Gruys
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

4.  Assignment of the prealbumin (PALB) gene (familial amyloidotic polyneuropathy) to human chromosome region 18q11.2-q12.1.

Authors:  R S Sparkes; H Sasaki; T Mohandas; K Yoshioka; I Klisak; Y Sakaki; C Heinzmann; M I Simon
Journal:  Hum Genet       Date:  1987-02       Impact factor: 4.132

5.  Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in Caenorhabditis elegans.

Authors:  Kayalvizhi Madhivanan; Erin R Greiner; Miguel Alves-Ferreira; David Soriano-Castell; Nirvan Rouzbeh; Carlos A Aguirre; Johan F Paulsson; Justin Chapman; Xin Jiang; Felicia K Ooi; Carolina Lemos; Andrew Dillin; Veena Prahlad; Jeffery W Kelly; Sandra E Encalada
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-30       Impact factor: 11.205

Review 6.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

7.  Haplotype analysis of familial amyloidotic polyneuropathy. Evidence for multiple origins of the Val----Met mutation most common to the disease.

Authors:  K Yoshioka; H Furuya; H Sasaki; M J Saraiva; P P Costa; Y Sakaki
Journal:  Hum Genet       Date:  1989-04       Impact factor: 4.132

8.  Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.

Authors:  Maria Rosário Almeida; Bárbara Macedo; Isabel Cardoso; Isabel Alves; Gregorio Valencia; Gemma Arsequell; Antoni Planas; Maria João Saraiva
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

9.  Familial amyloidotic polyneuropathy in Sweden: a pedigree analysis.

Authors:  U Drugge; R Andersson; F Chizari; M Danielsson; G Holmgren; O Sandgren; A Sousa
Journal:  J Med Genet       Date:  1993-05       Impact factor: 6.318

10.  Molecular analysis of a variant type of familial amyloidotic polyneuropathy showing cerebellar ataxia and pyramidal tract signs.

Authors:  H Furuya; K Yoshioka; H Sasaki; Y Sakaki; M Nakazato; H Matsuo; A Nakadai; S Ikeda; N Yanagisawa
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.